FDA Approves KEYTRUDA? (pembrolizumab) Plus LENVIMA? (lenvatinib) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma
- KEYTRUDA (200 mg intravenously [IV] every three weeks) in combination with LENVIMA (20 mg orally once daily); or
- Investigator?s choice, consisting of either doxorubicin (60 mg/m2?every three weeks) or paclitaxel (80 mg/m2?given weekly, three weeks on/one week off).
Endometrial Carcinoma (not MSI-H or dMMR) |
||
Endpoint |
KEYTRUDA 200 mg every 3 weeks and LENVIMA (n=346) |
Doxorubicin or Paclitaxel (n=351) |
OS |
||
Number (%) of patients with event |
165 (48%) |
203 (58%) |
Median in months (95% CI) |
17.4 (14.2, 19.9) |
12.0 (10.8, 13.3) |
Hazard ratio* (95% CI) |
0.68 (0.56, 0.84) |
|
p-value? |
0.0001 |
|
PFS |
||
Number (%) of patients with event |
247 (71%) |
238 (68%) |
Median in months (95% CI) |
6.6 (5.6, 7.4) |
3.8 (3.6, 5.0) |
Hazard ratio* (95% CI) |
0.60 (0.50, 0.72) |
|
p-value? |
<0.0001 |
|
Objective Response Rate |
||
ORR??(95% CI) |
30% (26, 36) |
15% (12, 19) |
Complete response |
5% |
3% |
Partial response |
25% |
13% |
p-value? |
<0.0001 |
|
Duration of Response |
n=105 |
n=53 |
Median in months (range) |
9.2 (1.6+, 23.7+) |
5.7 (0.0+, 24.2+) |
* Based on the stratified Cox regression model ??Based on stratified log-rank test ??Response: Best objective response as confirmed complete response or partial response ??Based on Miettinen and Nurminen method stratified by ECOG performance status, geographic region, and history of pelvic radiation |
- in combination with platinum- and fluoropyrimidine-based chemotherapy, or
- as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD L1 (CPS =10) as determined by an FDA approved test